T Cell News and Research

Latest T Cell News and Research

ProBioGen initiates clinical trials of Ebola vaccine using AGE1.CR.pIX cell line

ProBioGen initiates clinical trials of Ebola vaccine using AGE1.CR.pIX cell line

Ovizio unveils new in-line suspension cell-monitoring microscope at ESACT

Ovizio unveils new in-line suspension cell-monitoring microscope at ESACT

Scientists identify gene mutation that causes color blindness

Scientists identify gene mutation that causes color blindness

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

New finding may lead to development of immunity-based therapies for tuberculosis

New finding may lead to development of immunity-based therapies for tuberculosis

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Ariana Pharma joins the GastricGlycoExplorer consortium

Ariana Pharma joins the GastricGlycoExplorer consortium

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.